Pharmaceutical biotechnology products approved within the European Union

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 55, Issue 1, 2003, Pages 3-10

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Biopharmaceutical; European Medicines Evaluation Agency; Pharmaceutical biotechnology; Therapeutic protein

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BECAPLERMIN; BETA1A INTERFERON; CONSENSUS INTERFERON; DACLIZUMAB; DESULFATOHIRUDIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ETANERCEPT; HEPATITIS A HEPATITIS B VACCINE; IMIGLUCERASE; INFLIXIMAB; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; OSTEOGENIC PROTEIN 1; PALIVIZUMAB; PEGINTERFERON ALPHA2B; RASBURICASE; RECOMBINANT CYTOKINE; RECOMBINANT DNA; RECOMBINANT ENZYME; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT HORMONE; RITUXIMAB; SULESOMAB TC 99M; TRASTUZUMAB; UNINDEXED DRUG; VACCINE;

BIOTECHNOLOGY; DNA RECOMBINATION; DRUG APPROVAL; EUROPEAN UNION; GENOMICS; HUMAN; IMMUNOGENICITY; NONHUMAN; PROTEOMICS; REVIEW;

EID: 0037237634     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(02)00165-0     Document Type: Review

References (25)

1. Brooks G. Biotechnology in Healthcare. 1998;Pharmaceutical Press, London, UK.
2. Walsh G. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature. Eur. J. Pharm. Sci. 15:2002;135-138.
3. http://pharmacos.eudra.org.
4. http://www.emea.eu.int.
5. Carey P. Protein Engineering and Design. 1996;Academic Press, London, UK.
6. Fersht A. Structure and Mechanism in Protein Science. 1999;Freeman Ltd, Basingstoke, UK.
7. Kohler G., Milstein C. Continuous culture of fused cells secreting antibody of pre-defined specificity. Nature. 256:1975;495-497.
8. Berger M. Therapeutic applications of monoclonal antibodies. Am. J. Med. Sci. 324:(1):2002;14-30.
9. Bristrow A. Recombinant DNA derived insulin analogues as potentially useful therapeutic agents. Tibtech. 11:1993;301-305.
10. Chance R., Glazer N., Wishner K. Insulin lispro (humalog). Murphy G., Walsh B. Biopharmaceuticals, an Industrial Perspective. 1998;149-172 Kluwer Academic Publishers, Dordrecht, The Netherlands.
11. Katre N. The conjugation of proteins with polyethylene glycol and other polymers - altering properties of proteins to enhance their therapeutic potential. Adv. Drug Del. Revs. 10:(1):1993;91-114.
12. New biotechnology medicines in development report (2002). Available at http://phrma.org.
13. Wright G. High level expression of active human α 1-antitrypsin in the milk of transgenic sheep. Biotechnology. 9:1991;830-834.
14. Houdebine L. Transgenic animal bioreactors. Transgenic Res. 9:(4-5):2000;305-320.
15. Larrick J., Thomas D. Producing proteins in transgenic plants and animals. Curr. Opin. Biotechnol. 12:(4):2001;411-418.
16. Mason H. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol. Med. 8:(7):2002;324-329.
17. Patton J. Mechanism of macromolecule absorption by the lungs. Adv. Drug. Del. Revs. 19:(1):1996;3-36.
18. Patton J. Inhaled insulin. Adv. Drug Del. Revs. 35:1999;235-247.
19. Davis S. Nasal vaccines. Adv. Drug Del. Rev. 51:2001;21-42.
20. Pfeifer A., Verma I. Gene therapy: promises and problems. Ann. Rev. Genomics & Human. Genetics. 2:2001;177-211.
21. Phillips A. The challenge of gene therapy and DNA delivery. J. Pharm. Pharmacol. 53:(9):2001;1169-1174.
22. Stein A., Krieg A. Applied Antisense Oligonucleotide Technology. 1998;J. Wiley and Sons, Chichester, UK.
23. Lebedeva I., Stein C. Antisense oligonucleotides: promise and reality. Ann. Rev. Pharmacol. Toxicol. 41:2001;403-419.
24. Cunningham M. Genomics and proteomics, the new millennium of drug discovery and development. J. Pharmacol. Toxicol. Methods. 44:(1):2000;291-300.
25. Wang J., Hewick R. Proteomics in drug discovery. Drug discovery today. 4:(3):1999;129-133.